

PATENT
ATTORNEY DOCKET NO.: DIVER1260-3

Applicant: Short, et al.
Serial No.: 09/421,629
Filed: October 19, 1999
Page 7

The paragraph beginning at line 1 of page 11 has been amended to read as follows:

DI
Bak EG
Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g. the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic proteins, e.g enzymes, such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.

In the claims:

Claims 32, 33, and 43 through 47 have been rewritten to read as follows:

Gray Cary\GT\6255808.1
104703-158574

PATENT
ATTORNEY DOCKET NO.: DIVER1260-3

Applicant: Short, et al.
Serial No.: 09/421,629
Filed: October 19, 1999
Page 8

- D10*
but D10
32. (Amended) A method for identifying a bioactivity or biomolecule of interest comprising:
- a) culturing a gene expression library comprising a pool of expression constructs, each expression construct comprising a vector containing one or more cDNA or genomic DNA fragments, wherein the cDNA or genomic DNA fragments in the pool of expression constructs are derived from a plurality of species of donor organisms, wherein the library is formed by normalizing the representation of various DNAs within the cDNA or genomic DNA fragments so as to form a normalized library of cDNA or genomic DNA fragments; and
 - b) identifying the bioactivity or biomolecule of interest encoded by the cDNA or genomic DNA fragments in the normalized library.
33. (Amended) The method of claim 32, wherein the bioactivity is an enzymatic activity.

- D11*
but E11
43. (Amended) The method of claim 32, which comprises the step of recovering a fraction of the DNA having a desired characteristic.
44. (Amended) The method of claim 32 which comprises the step of amplifying the copy number of the cDNA or genomic DNA fragments.

Gray Cary\GT\6255808.1
104703-158574

PATENT
ATTORNEY DOCKET NO.: DIVER1260-3

Applicant: Short, et al.
Serial No.: 09/421,629
Filed: October 19, 1999
Page 9

D11
Rev E11
45. (Amended) The method of claim 32 wherein the step of amplifying the DNA precedes the normalizing step.

46. (Amended) The method of claim 32 wherein the step of normalizing the DNA precedes the amplifying step.

Concluded
47. (Amended) The method of claim 32 which comprises both the steps of (i) amplifying the copy number of the cDNA or genomic DNA fragments and (ii) recovering a fraction of the cDNA or genomic DNA fragments having a desired characteristic.

Gray Cary/GT/6255808.1
104703-158574